Literature DB >> 1925409

Immunoglobulin-mediated prevention of autoimmune diabetes in the non-obese diabetic (NOD) mouse.

S Forsgren1, A Andersson, V Hillörn, A Söderström, D Holmberg.   

Abstract

We investigated whether the development of spontaneous T-cell-mediated type I diabetes in NOD mice is influenced by B cells and immunoglobulin (Ig). During the first 4 weeks of life, B-cell development was suppressed by repeated administration of rabbit anti-mouse IgM (RaIgM), while controls received polyclonal rabbit Ig (NRIg). A reduction in the incidence of diabetes, as well as in development of insulitis, was observed after either of these treatments. However, the effect on insulitis was more pronounced in mice treated with RaIgM compared with those treated with NRIg. Furthermore, while the optimal effect of NRIg was obtained after a single injection at birth, the additional effect of RaIgM on development of insulitis was observed only after continued treatment for the first 4 weeks of life. Taken together these data suggest a possible role of Ig/B cells in the development of autoimmunity in the NOD mouse. The additional effect observed after continued suppression of the neonatal B-cell development suggests that this population may contribute significantly to the establishment of an auto-aggressive lymphocyte repertoire in the NOD mouse.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1925409     DOI: 10.1111/j.1365-3083.1991.tb01567.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  14 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  Viruses, cytokines, antigens, and autoimmunity.

Authors:  R Gianani; N Sarvetnick
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

3.  A multivalent vaccine for type 1 diabetes skews T cell subsets to Th2 phenotype in NOD mice.

Authors:  Ming S Lin; Hubert M Tse; Meghan M Delmastro; Suzanne Bertera; Caterina T Wong; Robert Lakomy; Jing He; Martha M Sklavos; Gina M Coudriet; Massimo Pietropaolo; Massimo M Trucco; Jon D Piganelli
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

4.  The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development.

Authors:  Alexandra I Ziegler; Melanie A Le Page; Mhairi J Maxwell; Jessica Stolp; Haoyao Guo; Abhirup Jayasimhan; Margaret L Hibbs; Pere Santamaria; Jacques F Miller; Magdalena Plebanski; Pablo A Silveira; Robyn M Slattery
Journal:  Diabetologia       Date:  2013-09-08       Impact factor: 10.122

5.  Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates.

Authors:  K S Sivasai; T Mohanakumar; D Phelan; S Martin; M E Anstey; D C Brennan
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

Review 6.  B cell depletion in autoimmune diabetes: insights from murine models.

Authors:  Jayne L Chamberlain; Kesley Attridge; Chun Jing Wang; Gemma A Ryan; Lucy Sk Walker
Journal:  Expert Opin Ther Targets       Date:  2011-03-03       Impact factor: 6.902

7.  Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice.

Authors:  A Nicoletti; S Kaveri; G Caligiuri; J Bariéty; G K Hansson
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

8.  B cells in autoimmune diabetes.

Authors:  F Susan Wong; Li Wen
Journal:  Rev Diabet Stud       Date:  2005-11-10

9.  Maternal immunity to insulin does not affect diabetes risk in progeny of non obese diabetic mice.

Authors:  K Koczwara; A-G Ziegler; E Bonifacio
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

Review 10.  Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases.

Authors:  Jean-François Bach
Journal:  Arthritis Res       Date:  2002-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.